WO1999038511A1 - Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques - Google Patents
Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques Download PDFInfo
- Publication number
- WO1999038511A1 WO1999038511A1 PCT/FR1998/001783 FR9801783W WO9938511A1 WO 1999038511 A1 WO1999038511 A1 WO 1999038511A1 FR 9801783 W FR9801783 W FR 9801783W WO 9938511 A1 WO9938511 A1 WO 9938511A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microgranules
- hydrophobic
- omeprazole
- substance
- microgranules according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Definitions
- the present invention relates to a galenical formulation of omeprazole in the form of gastroprotected microgranules having improved stability over time.
- the present invention further extends to the process for manufacturing said 0 microgranules, and to pharmaceutical preparations containing them
- Omeprazole or 5-methoxy-2 - [[(4-methoxy-3,5-d ⁇ methyl-2-pynd ⁇ nyl) methyljsulfinyl] - 1-be ⁇ z ⁇ m ⁇ dazole, is known as a powerful inhibitor of acid gastrointestinal secretion (Swedish patent n ° 78 04231), and can be used for the treatment of gastric and duodenal ulcers
- omeprazole degrades easily in an acid medium and in a neutral medium.
- the degradation half-life of omeprazole is ten minutes at pH less than 4, eighteen hours at pH 6.5 and approximately 300 days at 0 pH 11
- omeprazole is also affected by humidity, heat, the presence of organic solvents even in trace amounts, and light to a lesser degree.
- Organic solvents are generally used in the process of manufacture of omeprazole formulations, which we wish to avoid for ecological reasons
- the active principle is often combined with an excipient such as:
- an alkaline substance for example a sodium, potassium, calcium or aluminum salt, an organic acid, such as phosphoric acid, carbonic acid or l 'citric acid.
- an anti-acid substance for example an aluminum, magnesium or calcium oxide or hydroxide
- a pharmaceutically acceptable organic buffer substance such as a basic amino acid or a salt thereof, in particular trihydroxymethylaminomethane
- an inert substance such as mannitol (see patent application EP-646 006) or titanium dioxide (see patent application WO 96/37 195), • a dehydrating agent during the final conditioning of the formulation.
- the stability of the formulations of the prior art is insufficient and the aim of the present invention is to provide a formulation of gastroprotected omeprazole microgranules, stable to coloring, whose long-term storage stability is improved, and which also has the desired therapeutic properties, that is to say a certain resistance to dissolution in an acid medium, and rapid solubility in a neutral medium.
- the object of the present invention is therefore to provide gastroprotected omeprazole microgranules having dissolution profiles corresponding to the intended therapeutic application and which are advantageously stable over time.
- the present invention relates to a new formulation of gastroprotected omeprazole containing at least one hydrophobic substance chosen to increase the stability of the active principle while obtaining the desired dissolution profile.
- the Applicant has in particular optimized the composition of such a formulation by selecting combinations of several hydrophobic substances to achieve the objective of the present invention.
- omeprazole microgranules which are the subject of the present invention are advantageously lacking: • alkaline compounds in the form of salts,
- ionic surfactants such as lauryl sulfate commonly used to stabilize omeprazole
- the omeprazole microgranules according to the invention each comprise an active layer containing the active principle, and an external gastroprotection layer containing a gastroprotective agent and are characterized in that they contain at least one hydrophobic substance.
- Hydrophobic substances will be chosen which do not react chemically with omeprazole, which can be easily used during formulation, which are compatible with the excipients used and which allow the desired dissolution and release profiles to be obtained. targeted therapeutic application.
- the hydrophobic substance preferably represents between 5 and 40% by weight of the omeprazole.
- the active layer containing the omeprazole is advantageously coated with at least one protective layer.
- This protective layer may contain a diluting substance or a coating agent associated with a hydrophobic plasticizer.
- a hydrophobic agent may be associated with the gastroprotection agent, preferably chosen from glycerides.
- the microgranules according to the invention use a combination of different hydrophobic agents making it possible to improve the stability of the formulation.
- the microgranules according to the invention comprise: An active ingredient layer containing omeprazole, a binder chosen from all pharmaceutically acceptable binders, a hydrophobic substance and a solubilizing substance for the active ingredient,
- a gastroprotection layer containing an enteric film-forming agent, a plasticizer and a hydrophobic substance.
- the active principle layer advantageously comprises a hydrophobic substance of the fatty substance type advantageously chosen from silicone oils: it preferably represents between 5 and 40% of the weight of active principle.
- a nonionic surfactant preferably chosen from polysorbates (Montanox 80® or Montane 20-60®).
- the active layer advantageously comprises a binder chosen from pharmaceutically acceptable binders, in this case hydroxypropylmethylcellulose whose mass proportion represents 30 to 50% relative to the weight of active principle.
- the first protective layer advantageously comprises an inert substance chosen particularly from pharmaceutically acceptable diluents including mannitol (which is non-hygroscopic) in a mass proportion of 100 to 300% and, preferably, 200% of the weight of the active principle.
- pharmaceutically acceptable diluents including mannitol (which is non-hygroscopic) in a mass proportion of 100 to 300% and, preferably, 200% of the weight of the active principle.
- This layer also comprises a binder chosen from pharmaceutically acceptable binders, advantageously hydroxypropylmethylcellulose, in a proportion of 10 to 30% and, preferably, 20% of the weight of mannitol.
- a lubricant chosen from pharmaceutically acceptable lubricants, in this case talc (which is non-hygroscopic) in proportion from 0 to 100% of the weight of the active principle.
- the second protective layer consists of a water-soluble coating agent chosen from pharmaceutically acceptable film-forming agents and advantageously hydroxypropylmethylcellulose in a proportion of 1 to 10%, preferably 5%, of the weight of microgranules obtained after assembly of the first layer. protection.
- a hydrophobic plasticizer such as Myvacet® will be used in a proportion of 10 to 30% of the dry varnish of the chosen coating agent.
- a lubricating agent chosen from pharmaceutically acceptable lubricants, advantageously talc (which is non-hygroscopic), in a proportion of 10 to 50%, preferably 15% of the dry varnish of the coating agent retained.
- the external gastroprotection layer contains a protective film-forming agent, advantageously a methacrylic acid copolymer, such as Eudragit L30D®, in a proportion of 15 to 30%, preferably 20%, of dry deposition of polymer relative to the mass. of microgranules treated.
- a protective film-forming agent advantageously a methacrylic acid copolymer, such as Eudragit L30D®, in a proportion of 15 to 30%, preferably 20%, of dry deposition of polymer relative to the mass. of microgranules treated.
- one or more hydrophobic substances chosen by the waxes and oils often used in the pharmaceutical industry preferably gelucire 50-13®, will be included in the gastroprotective film-forming agent, in a proportion of 5 to 20% of the dry varnish of the film agent retained.
- a plasticizer chosen from pharmaceutically acceptable plasticizers preferably triethyl citrate, representing from 5 to 20%, advantageously 10%, of the dry varnish weight of the film-forming agent retained, may optionally be used for the external gastroprotection layer.
- a lubricating agent chosen from pharmaceutically acceptable lubricants, advantageously talc will be used.
- the active layer is mounted on a neutral core consisting for example of sucrose and starch, the diameter of which is between 700 and 900 microns.
- microgranules according to the invention will preferably have a particle size of between 0.5 and 3 mm, more preferably between 0.7 and 2 mm.
- the present invention also relates to a process for preparing the microgranules according to the invention. This process is characterized in that it is carried out in an aqueous medium, without the use of any organic solvent.
- microgranules described in the present invention will be obtained by using any equipment suitable for the preparation and coating of microgranules, well known to those skilled in the art and, in particular, equipment of the conventional turbine, perforated turbine or bed type type. fluidized air.
- the microgranules according to the invention are obtained by mounting on a neutral core, preferably in a fluidized air bed, by successive sprays:
- microgranules according to the invention are mounted on a neutral core in a fluidized air bed, by successive sprays:
- Each spraying step is advantageously followed by sieving and drying at a temperature below the melting temperature of each of the compounds forming part of the microgranules in said step.
- microgranules obtained according to this process advantageously contain less than 1.5%, preferably 0.5% by weight of water.
- a subject of the present invention is finally the pharmaceutical preparations containing the micro-granules according to the invention capable of being obtained by the process described above, these preparations will advantageously be in the form of capsules containing 5 to 60 mg approximately of omeprazole.
- FIG. 1 represents the curve of dissolution in vitro at pH 6.8 of capsules according to the invention (curve a) compared to that of an oral formulation of omeprazole of the prior art (curve b).
- FIG. 2 represents the in vivo dissolution curve of capsules according to the invention (courbel) compared to that of an oral formulation of omeprazole
- FIG. 3 represents the evolution over time of the average plasma concentration in omeprazole of 10 patients to whom a formulation of the invention has been administered (curve A1), and of these same 10 patients to whom a formulation of prior art (curve B).
- FIG. 4 represents the evolution over time of the average plasma concentration in omeprazole of 10 patients to whom a formulation of the invention has been administered (curve A2), and of these same 10 patients to whom a formulation has been administered of the prior art (curve C).
- Microgranules are prepared in an OHLMAN type fluidized air bed apparatus.
- a suspension of the active ingredient having the composition below is prepared.
- the purified water is stirred and the Pharmacoat 603® (manufactured by SEPPIC), Polysorbate 80® (manufactured by SEPPIC), Dimethicone (manufactured by LAMBERT and RIVIERE) and omeprazole are added successively.
- the agitation of the suspension is maintained throughout the assembly of the Neutrals 20® (manufactured by NP PHARM) placed in the fluidized air bed.
- the coated Neutrals® are then sieved, and dried for four hours at approximately 50 ° C.
- a preassembly suspension consisting of 4% by weight of Pharmacoat 603®, 20% by weight of Mannitol 25® (both manufactured by ROQUETTE) and 76% of purified water is prepared.
- a preassembly suspension of the following composition is prepared.
- This pre-assembly step is carried out under the same conditions as the Pharmacoat® / Mannitol pre-assembly step.
- the temperature of the granules is maintained between 26 and 28 ° C. during the spraying of the suspension.
- a coating suspension of the following composition is prepared:
- coated microgranules are then sieved and dried at approximately 45 ° C for four hours, then lubricated with talc.
- Microgranules are prepared according to the method of Example 1, in order to obtain the following formulations A and B.
- the stability of the unconditioned formulation A is evaluated over time under real storage conditions (i.e. at 25 ° C. and 40% relative humidity).
- microgranules A and B prepared in Example 2 are conditioned in size 2 capsules, respectively marked G A and G B.
- a first study is carried out under accelerated aging conditions, according to a standardized ICH test (at 40 ° C. and 75% relative humidity).
- the stability tests as a function of time of the capsules G A and G B are carried out by placing the capsules in opaque polyethylene bottles.
- the impurities are measured by UN spectrometry. after separation by high performance liquid chromatography.
- the dosage of active principle and the water content are respectively carried out according to the standards USP ⁇ 905> and USP ⁇ 921>.
- Table 3 shows the increased stability of the microgranules according to the present invention compared to a formulation of the prior art sold by the ASTRA company under the brand name Mopral® (patent EP-247,983). 13
- A1 a formulation according to the invention
- B a formulation of the prior art sold under the brand name Losec® by the company ASTRA.
- This randomized study is carried out on 10 patients who are administered a single dose of 20 mg of microgranules according to the invention.
- the plasma omeprazole concentration is monitored for eight hours after administration.
- FIG. 3 represents the evolution of the average plasma concentration of omeprazole (measured on the 10 patients) calculated for A1 and then for B.
- Table 4 gives the average value of the main bioavailability parameters corresponding to the two curves A1 and B. TABLE 4
- A2 a formulation according to the invention denoted A2
- C a formulation of the prior art denoted C marketed under the brand Prilosec® by the company MERCK.
- FIG. 4 represents the evolution over time of the average plasma omeprazole concentration of the 10 patients measured for A2 and C.
- Table 5 gives the average value of the main bioavailability parameters corresponding to the two curves A2 and C.
Abstract
Description
Claims
Priority Applications (22)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU90748/98A AU755882B2 (en) | 1998-01-30 | 1998-08-10 | Gastroprotected omerprazole microgranules, method for obtaining same and pharmaceutical preparations |
HU0100347A HU229956B1 (hu) | 1998-01-30 | 1998-08-10 | Gyomorvédett omeprazol mikrogranulátumok, eljárás előállításukra és ezeket tartalmazó gyógyászati készítmények |
SK1141-2000A SK285666B6 (sk) | 1998-01-30 | 1998-08-10 | Mikrogranuly omeprazolu s vonkajšou vrstvou, ktorá chráni pred žalúdočným prostredím, spôsob prípravy mikrogranúl |
EEP200000466A EE05620B1 (et) | 1998-01-30 | 1998-08-10 | Omeprasooli mikrograanulid, nende valmistamismeetod ja farmatseutilised preparaadid |
JP2000529244A JP4286452B2 (ja) | 1998-01-30 | 1998-08-10 | 胃において保護されるオメプラゾール微粒子、その製造方法および医薬製剤 |
BRPI9814924-5A BR9814924B1 (pt) | 1998-01-30 | 1998-08-10 | microgránulos de omeprazol, processo de preparação dos mesmos, e, preparações farmacêuticas. |
DK98942718.2T DK1051174T4 (da) | 1998-01-30 | 1998-08-10 | Gastrobeskyttede omeprazolmikrogranula, fremgangsmåde til opnåelse deraf og farmaceutiske præparater |
US09/601,213 US6551621B1 (en) | 1998-01-30 | 1998-08-10 | Gastroprotected omeprazole microgranules, method for obtaining same and pharmaceutical preparations |
PL342044A PL200043B1 (pl) | 1998-01-30 | 1998-08-10 | Mikrogranulki z omeprazolem, sposób wytwarzania i preparaty farmaceutyczne |
ES98942718T ES2189232T5 (es) | 1998-01-30 | 1998-08-10 | Microgránulos de omeprazol protegidos gástricamente, procedimiento de obtención y preparaciones farmacéuticas |
SI9830349T SI1051174T2 (sl) | 1998-01-30 | 1998-08-10 | Gastroprotektirane omeprazolne mikrogranule, postopek za pridobivanje le-teh in farmacevtski pripravki |
NZ505998A NZ505998A (en) | 1998-01-30 | 1998-08-10 | Gastroprotected omeprazole microgranules, method for obtaining same and pharmaceutical preparations |
DE69811278T DE69811278T3 (de) | 1998-01-30 | 1998-08-10 | Gegen magensaft geschützte omeprazol-mikrogranülen, herstellungsverfahren und pharmazeutische zubereitungen |
EP98942718A EP1051174B2 (fr) | 1998-01-30 | 1998-08-10 | Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques |
CA002319015A CA2319015C (fr) | 1998-01-30 | 1998-08-10 | Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques |
EA200000797A EA002879B1 (ru) | 1998-01-30 | 1998-08-10 | Микрогранулы омепразола, защищенные от желудочного сока, способ их получения и фармацевтические препараты |
IL13753698A IL137536A0 (en) | 1998-01-30 | 1998-08-10 | Gastroprotected omeprazole microgranules, method for obtaining same and pharmaceutical preparations |
AT98942718T ATE232100T1 (de) | 1998-01-30 | 1998-08-10 | Gegen magensaft geschützte omeprazol- mikrogranülen, herstellungsverfahren und pharmazeutische zubereitungen |
UA2000085071A UA61988C2 (uk) | 1998-01-30 | 1998-10-08 | Мікрогранули омепразолу, захищені від шлункового соку, спосіб їхнього одержання і фармацевтичний препарат |
IS5577A IS2866B (is) | 1998-01-30 | 2000-07-25 | Magavarin ómeprasólörkorn, aðferð til að fá slík og lyfjaefnablöndur |
NO20004654A NO330144B1 (no) | 1998-01-30 | 2000-09-18 | Gastrobeskyttede omeprazolmikrogranuler, fremgangsmate for a oppna slike og farmasoytiske preparater |
HK01102965A HK1032354A1 (en) | 1998-01-30 | 2001-04-25 | Gastroprotected omerprazole microgranules, method for obtaining same and pharmaceutical preparations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9801098A FR2774288B1 (fr) | 1998-01-30 | 1998-01-30 | Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques |
FR98/01098 | 1998-01-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999038511A1 true WO1999038511A1 (fr) | 1999-08-05 |
Family
ID=9522415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1998/001783 WO1999038511A1 (fr) | 1998-01-30 | 1998-08-10 | Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques |
Country Status (32)
Country | Link |
---|---|
US (1) | US6551621B1 (fr) |
EP (1) | EP1051174B2 (fr) |
JP (1) | JP4286452B2 (fr) |
KR (1) | KR100510366B1 (fr) |
CN (1) | CN1114405C (fr) |
AT (1) | ATE232100T1 (fr) |
AU (1) | AU755882B2 (fr) |
BG (1) | BG65087B1 (fr) |
BR (1) | BR9814924B1 (fr) |
CA (1) | CA2319015C (fr) |
CZ (1) | CZ299192B6 (fr) |
DE (1) | DE69811278T3 (fr) |
DK (1) | DK1051174T4 (fr) |
EA (1) | EA002879B1 (fr) |
EE (1) | EE05620B1 (fr) |
ES (1) | ES2189232T5 (fr) |
FR (1) | FR2774288B1 (fr) |
GE (1) | GEP20032941B (fr) |
HK (1) | HK1032354A1 (fr) |
HU (1) | HU229956B1 (fr) |
IL (1) | IL137536A0 (fr) |
IS (1) | IS2866B (fr) |
NO (1) | NO330144B1 (fr) |
NZ (1) | NZ505998A (fr) |
PL (1) | PL200043B1 (fr) |
PT (1) | PT1051174E (fr) |
RS (1) | RS50245B (fr) |
SI (1) | SI1051174T2 (fr) |
SK (1) | SK285666B6 (fr) |
TR (1) | TR200002214T2 (fr) |
UA (1) | UA61988C2 (fr) |
WO (1) | WO1999038511A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2793688A1 (fr) * | 1999-05-21 | 2000-11-24 | Ethypharm Lab Prod Ethiques | Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques |
US9238029B2 (en) | 2004-06-16 | 2016-01-19 | Takeda Pharmaceuticals U.S.A., Inc. | Multiple PPI dosage form |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2790668B1 (fr) * | 1999-03-12 | 2002-07-26 | D B F | Granules contenant une substance vegetale et leur procede de preparation |
FR2845289B1 (fr) * | 2002-10-04 | 2004-12-03 | Ethypharm Sa | Spheroides, procede de preparation et compositions pharmaceutiques. |
CA2517005A1 (fr) * | 2003-02-20 | 2004-09-02 | Santarus, Inc. | Liberation immediate d'un complexe antacide d'omeprazole presentant une nouvelle formulation pour une elimination rapide et prolongee d'acide gastrique |
US20050220870A1 (en) * | 2003-02-20 | 2005-10-06 | Bonnie Hepburn | Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
ES2234393B2 (es) * | 2003-04-29 | 2006-09-01 | Laboratorios Belmac, S.A. | "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido". |
MXPA06000529A (es) * | 2003-07-18 | 2006-08-11 | Santarus Inc | Formulaciones farmaceuticas utiles para inhibir la secrecion de acido y metodos para elaborarlas y utilizarlas. |
WO2005007117A2 (fr) * | 2003-07-18 | 2005-01-27 | Santarus, Inc. | Formulation pharmaceutique et procede de traitement de troubles gastro-intestinaux lies a l'acidite |
US8993599B2 (en) * | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
CN1874764B (zh) * | 2003-10-10 | 2012-08-01 | 埃法尔姆公司 | 含有银杏提取物的持续释放微粒及其制备方法 |
US20070292498A1 (en) * | 2003-11-05 | 2007-12-20 | Warren Hall | Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers |
CA2554271A1 (fr) * | 2004-02-10 | 2005-08-25 | Santarus, Inc. | Combinaison d'un inhibiteur de la pompe a protons, d'un tampon et d'un medicament anti-inflammatoire non steroidien |
JP2007532677A (ja) * | 2004-04-16 | 2007-11-15 | サンタラス インコーポレイティッド | プロトンポンプ阻害剤、緩衝剤、および運動促進薬の組み合わせ |
US8815916B2 (en) * | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8906940B2 (en) * | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
WO2007078874A2 (fr) * | 2005-12-30 | 2007-07-12 | Cogentus Pharmaceuticals, Inc. | Formulations pharmaceutiques à usage oral contenant des médicaments anti-inflammatoires non stéroïdiens et des inhibiteurs d'acides |
TR201816133T4 (tr) | 2006-04-04 | 2018-11-21 | Kg Acquisition Llc | Bi̇r anti̇platelet ajan ve bi̇r asi̇t i̇nhi̇bi̇törü i̇çeren oral dozaj formlari. |
WO2007138606A2 (fr) * | 2006-06-01 | 2007-12-06 | Dexcel Pharma Technologies Ltd. | Formulation pharmaceutique comprenant des unités multiples |
US20090092658A1 (en) * | 2007-10-05 | 2009-04-09 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
BRPI0717613A2 (pt) * | 2006-10-17 | 2013-10-22 | Ranbaxy Lab Ltd | Composição em comprimido de múltiplas unidades, processo para o preparo do mesmo e método para inibir a secreção de ácido gástrico |
CN104519888A (zh) | 2011-12-28 | 2015-04-15 | 波曾公司 | 用于递送奥美拉唑和乙酰水杨酸的改良组合物和方法 |
US20170042806A1 (en) | 2015-04-29 | 2017-02-16 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
EP3117824A1 (fr) | 2015-07-17 | 2017-01-18 | BE Pharbel Manufacturing | Microparticules multicouche à libération de composé pharmaceutiquement actif sous forme posologique liquide |
ES2944568T3 (es) | 2015-07-17 | 2023-06-22 | Be Pharbel Mfg | Micropartículas multicapa de liberación de compuestos farmacéuticamente activos en forma de dosificación líquida |
WO2017145146A1 (fr) | 2016-02-25 | 2017-08-31 | Dexcel Pharma Technologies Ltd. | Compositions comprenant des inhibiteurs de la pompe à protons |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
FR3078630B1 (fr) | 2018-03-08 | 2021-05-14 | Karim Ioualalen | Mode de formulation sous forme de solide divise hydrophobe |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0247983A2 (fr) | 1986-04-30 | 1987-12-02 | Aktiebolaget Hässle | Préparation pharmaceutique pour utilisation orale |
EP0342522A1 (fr) * | 1988-05-18 | 1989-11-23 | Eisai Co., Ltd. | Préparation orale à base d'un composé instable aux acides |
WO1993025204A1 (fr) * | 1992-06-16 | 1993-12-23 | Ethypharm | Compositions stables de microgranules d'omeprazole gastro-proteges et leur procede d'obtention |
WO1996001624A1 (fr) | 1994-07-08 | 1996-01-25 | Astra Aktiebolag | Preparation pharmaceutique composite renfermant un inhibiteur de pompe a protons |
WO1996037195A1 (fr) | 1995-05-24 | 1996-11-28 | Mepha Ag | Nouvelle formulation pharmaceutique de pellets |
WO1997012581A2 (fr) * | 1995-09-21 | 1997-04-10 | Pharma Pass L.L.C. | Nouvelle composition contenant un omeprazole metastable a l'acide et procede de preparation |
WO1998019668A1 (fr) | 1996-11-06 | 1998-05-14 | Sharmatek, Inc. | Mode d'administration differee de medicaments sensibles aux acides |
WO1998052564A1 (fr) * | 1997-05-23 | 1998-11-26 | Cipla Limited | Composition pharmaceutique contenant du benzimidazole et procede de preparation |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9302396D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
WO1996010624A1 (fr) * | 1994-09-30 | 1996-04-11 | Medical Security Corporation | Procede et systeme servant a effectuer un traitement nettoyant et antiderapant de revetements de surfaces |
ES2094694B1 (es) † | 1995-02-01 | 1997-12-16 | Esteve Quimica Sa | Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion. |
SE9704869D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulaton II |
SE9704870D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
-
1998
- 1998-01-30 FR FR9801098A patent/FR2774288B1/fr not_active Expired - Lifetime
- 1998-08-10 CN CN98813805A patent/CN1114405C/zh not_active Expired - Lifetime
- 1998-08-10 HU HU0100347A patent/HU229956B1/hu unknown
- 1998-08-10 RS YU48400A patent/RS50245B/sr unknown
- 1998-08-10 CA CA002319015A patent/CA2319015C/fr not_active Expired - Lifetime
- 1998-08-10 CZ CZ20002709A patent/CZ299192B6/cs not_active IP Right Cessation
- 1998-08-10 NZ NZ505998A patent/NZ505998A/en not_active IP Right Cessation
- 1998-08-10 AU AU90748/98A patent/AU755882B2/en not_active Expired
- 1998-08-10 AT AT98942718T patent/ATE232100T1/de active
- 1998-08-10 JP JP2000529244A patent/JP4286452B2/ja not_active Expired - Fee Related
- 1998-08-10 US US09/601,213 patent/US6551621B1/en not_active Expired - Lifetime
- 1998-08-10 DE DE69811278T patent/DE69811278T3/de not_active Expired - Lifetime
- 1998-08-10 WO PCT/FR1998/001783 patent/WO1999038511A1/fr active IP Right Grant
- 1998-08-10 KR KR10-2000-7008363A patent/KR100510366B1/ko not_active IP Right Cessation
- 1998-08-10 SI SI9830349T patent/SI1051174T2/sl unknown
- 1998-08-10 GE GEAP19985533A patent/GEP20032941B/en unknown
- 1998-08-10 EA EA200000797A patent/EA002879B1/ru not_active IP Right Cessation
- 1998-08-10 EE EEP200000466A patent/EE05620B1/xx unknown
- 1998-08-10 PT PT98942718T patent/PT1051174E/pt unknown
- 1998-08-10 TR TR2000/02214T patent/TR200002214T2/xx unknown
- 1998-08-10 PL PL342044A patent/PL200043B1/pl unknown
- 1998-08-10 SK SK1141-2000A patent/SK285666B6/sk not_active IP Right Cessation
- 1998-08-10 ES ES98942718T patent/ES2189232T5/es not_active Expired - Lifetime
- 1998-08-10 DK DK98942718.2T patent/DK1051174T4/da active
- 1998-08-10 IL IL13753698A patent/IL137536A0/xx not_active IP Right Cessation
- 1998-08-10 BR BRPI9814924-5A patent/BR9814924B1/pt not_active IP Right Cessation
- 1998-08-10 EP EP98942718A patent/EP1051174B2/fr not_active Expired - Lifetime
- 1998-10-08 UA UA2000085071A patent/UA61988C2/uk unknown
-
2000
- 2000-07-25 BG BG104634A patent/BG65087B1/bg unknown
- 2000-07-25 IS IS5577A patent/IS2866B/is unknown
- 2000-09-18 NO NO20004654A patent/NO330144B1/no not_active IP Right Cessation
-
2001
- 2001-04-25 HK HK01102965A patent/HK1032354A1/xx not_active IP Right Cessation
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0247983A2 (fr) | 1986-04-30 | 1987-12-02 | Aktiebolaget Hässle | Préparation pharmaceutique pour utilisation orale |
EP0342522A1 (fr) * | 1988-05-18 | 1989-11-23 | Eisai Co., Ltd. | Préparation orale à base d'un composé instable aux acides |
WO1993025204A1 (fr) * | 1992-06-16 | 1993-12-23 | Ethypharm | Compositions stables de microgranules d'omeprazole gastro-proteges et leur procede d'obtention |
EP0646006A1 (fr) | 1992-06-16 | 1995-04-05 | Ethypharm Sa | Compositions stables de microgranules d'omeprazole gastro-proteges et leur procede d'obtention. |
WO1996001624A1 (fr) | 1994-07-08 | 1996-01-25 | Astra Aktiebolag | Preparation pharmaceutique composite renfermant un inhibiteur de pompe a protons |
WO1996037195A1 (fr) | 1995-05-24 | 1996-11-28 | Mepha Ag | Nouvelle formulation pharmaceutique de pellets |
WO1997012581A2 (fr) * | 1995-09-21 | 1997-04-10 | Pharma Pass L.L.C. | Nouvelle composition contenant un omeprazole metastable a l'acide et procede de preparation |
WO1998019668A1 (fr) | 1996-11-06 | 1998-05-14 | Sharmatek, Inc. | Mode d'administration differee de medicaments sensibles aux acides |
WO1998052564A1 (fr) * | 1997-05-23 | 1998-11-26 | Cipla Limited | Composition pharmaceutique contenant du benzimidazole et procede de preparation |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2793688A1 (fr) * | 1999-05-21 | 2000-11-24 | Ethypharm Lab Prod Ethiques | Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques |
WO2000071121A1 (fr) * | 1999-05-21 | 2000-11-30 | Laboratoires Des Produits Ethiques Ethypharm | Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques |
US8409612B1 (en) | 1999-05-21 | 2013-04-02 | Ethypharm | Microgranules insoluble in gastric fluid, method for obtaining same and pharmaceutical preparations |
US9238029B2 (en) | 2004-06-16 | 2016-01-19 | Takeda Pharmaceuticals U.S.A., Inc. | Multiple PPI dosage form |
US9889152B2 (en) | 2004-06-16 | 2018-02-13 | Takeda Pharmaceuticals U.S.A., Inc. | Multiple PPI dosage form |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1051174B1 (fr) | Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques | |
CA2739018C (fr) | Forme pharmaceutique orale a base de microgranules a liberation prolongee resistantes a l'alcool | |
EP1178799B1 (fr) | Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques | |
EP0868184B1 (fr) | Microgranules a liberation prolongee contenant du diltiazem comme principe actif | |
EP1627631A2 (fr) | Microgranules de sulfate de morphine, procédé de préparation et composition les contenant | |
EP1549298B1 (fr) | Spheroides procede de preparation et compositions pharmaceutiques | |
EP1515704B1 (fr) | Microcapsules pour la liberation retardee et controlee du perindopril | |
CA2280980A1 (fr) | Composition pharmaceutique pour la liberation programmee de dexfenfluramine | |
FR2742050A1 (fr) | Nouvelle composition contenant un benzimidazole acido-labile et son procede de preparation | |
FR2747573A1 (fr) | Nouvelle composition contenant un benzimidazole acido-labile et son procede de preparation | |
FR2745181A1 (fr) | Nouvelle composition contenant un benzimidazole acido-labile et son procede de preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-484/00 Country of ref document: YU Ref document number: 98813805.0 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: PV2000-2709 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 137536 Country of ref document: IL Ref document number: 505998 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2319015 Country of ref document: CA Ref document number: 2319015 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11412000 Country of ref document: SK Ref document number: 90748/98 Country of ref document: AU Ref document number: 2000/02214 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007008363 Country of ref document: KR Ref document number: PA/A/2000/007515 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998942718 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200000797 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09601213 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1998942718 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV2000-2709 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007008363 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998942718 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 90748/98 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020007008363 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: PV2000-2709 Country of ref document: CZ |